1. Home
  2. DRD vs DNLI Comparison

DRD vs DNLI Comparison

Compare DRD & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DRDGOLD Limited

DRD

DRDGOLD Limited

HOLD

Current Price

$31.16

Market Cap

3.4B

ML Signal

HOLD

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

HOLD

Current Price

$19.18

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRD
DNLI
Founded
1895
2013
Country
South Africa
United States
Employees
3410
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.3B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
DRD
DNLI
Price
$31.16
$19.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
13
Target Price
$32.63
$34.27
AVG Volume (30 Days)
312.2K
1.7M
Earning Date
08-19-2026
05-05-2026
Dividend Yield
1.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$36.69
N/A
Revenue Next Year
$27.25
$444.50
P/E Ratio
$15.32
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.08
$12.04
52 Week High
$39.37
$23.77

Technical Indicators

Market Signals
Indicator
DRD
DNLI
Relative Strength Index (RSI) 52.09 45.78
Support Level $29.40 $18.42
Resistance Level $32.61 $20.12
Average True Range (ATR) 1.34 1.22
MACD 0.54 -0.08
Stochastic Oscillator 73.56 24.11

Price Performance

Historical Comparison
DRD
DNLI

About DRD DRDGOLD Limited

DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Share on Social Networks: